Filter posts

The Ethics of the Market Access Debate

At the core of the market access conversation lies the question of value. How much …

A Bright Future for Orphan Disease Indications

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved …

Navigating the Rare Disease World

The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled …

Orphan Drugs: Making Rare Diseases Rarer

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving …

FDASIA: A Step Forward for Patients

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act …

BIO Investor Forum - Raring to Go: The Race to Treat Ultra-Rare Diseases

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering …

New Rare Disease Miniseries

Calling all biopharma researchers! Morning show “The Balancing Act” is producing a miniseries called “Roulette …

2012 Orphan Disease Forum: Addressing Today’s Opportunities and Challenges

If all of the people with rare disease lived in one country, it would be …

BIO Europe Spring 2012 - Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public …